

## Västra Hamnen Corporate Finance initiates coverage of Xintela

Xintela has entered into an agreement regarding commissioned equity research with Västra Hamnen Corporate Finance AB. The analysis includes a review of the company, its products, markets and competitors, as well as a financial scenario that forms the basis for an overall assessment of the company's justified market capitalisation. Västra Hamnen will monitor the development of Xintela and update the analysis on an ongoing basis.

In the initial analysis, Västra Hamnen Corporate Finance writes, among other things:

"Our view is that Xintela's current market cap does not reflect the potential of its pipeline. In Xintela we find a broad promising pipeline, a strong IP situation, a supportive main shareholder and high interest from the industry for the indication areas."

Read the full report at Västra Hamnen Corporate Finance's website:

<https://www.vhcorp.se/en/news/vaestra-hamnen-initiates-coverage-of-xintela>

### Contacts

---

#### **Xintela AB (publ)**

Evvy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: [evvy@xintela.se](mailto:evvy@xintela.se)

Medicon Village

223 81 Lund, Sweden

[www.xintela.se](http://www.xintela.se)



## About Xintela

---

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin  $\alpha 10\beta 1$  which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin  $\alpha 10\beta 1$  (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

## Attachments

---

[Västra Hamnen Corporate Finance initiates coverage of Xintela](#)